FCS Signals Next Chapter of Growth With Planned Leadership Transition and Focus on Innovation

Fort Myers, Fla., March 3, 2026 — After more than 23 years of combined service and executive leadership, Lucio N. Gordan, MD, has announced plans to transition from his role as president & managing physician of Florida Cancer Specialists & Research Institute (FCS), effective December 31, 2026.

Dr. Gordan will remain an integral part of FCS, continuing in his current role through the transition period and supporting a seamless handoff to his successor, David Wenk, MD, who will assume the role of president & managing physician on January 1, 2027. As part of a long-term succession plan, Dr. Gordan will assume the title of chair emeritus in 2027.

In addition, Dr. Gordan has been appointed chief of clinical innovation at McKesson, where he will collaborate with leadership across McKesson Oncology & Multispecialty business, to advance scalable clinical innovation, infrastructure, and growth across the oncology and multispecialty ecosystem. He will begin this role effective January 1, 2027.

This thoughtful transition reflects a strategic and collaborative plan designed to ensure continuity, stability, and long-term growth at FCS, and underscores the practice’s commitment to thoughtful succession planning while continuing to advance innovation in community oncology. As a result, FCS is well-positioned to continue building on its 40 plus-year legacy of delivering world-class cancer care in communities throughout Florida and beyond.

Beginning in 2027, Dr. Gordan will continue his longstanding commitment to FCS by maintaining an active clinical practice and providing leadership across key strategic priorities, including real-world evidence (RWE), informatics, therapeutics, clinical research, and business development.

“This next chapter is both humbling and energizing,” said Dr. Gordan. “It has been the privilege of my career to serve as president & managing physician at FCS. While my role will evolve, my commitment to our patients and to our colleagues remains as strong as ever. I look forward to continuing to bring impactful innovation and sustainable growth to our teams and the broader oncology community.”

Leaders across the organization expressed their appreciation for Dr. Gordan’s enduring impact.

“Dr. Gordan is an extraordinary leader whose vision, dedication, and clinical expertise have left an indelible mark on Florida Cancer Specialists & Research Institute,” said Dr. Wenk. “Throughout his tenure, he has led with unwavering commitment — advancing patient care, expanding research, and strengthening FCS’ position as a national leader in oncology. We are profoundly grateful for his service and leadership and look forward to his continued contributions in his new role as president emeritus and as chief of clinical innovation at McKesson.”

Under Dr. Gordan’s leadership, FCS has grown into one of the nation’s largest community oncology practices, expanding access to cutting-edge clinical trials, advancing value-based care initiatives, and strengthening partnerships.

This expanded role will enable Dr. Gordan to build upon his longstanding work with FCS while scaling clinical excellence and innovation efforts across The Network and the broader oncology community.